Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.
Read twice and referred to the Committee on Finance.
Bruce Westerman bought PFE
Bruce Westerman bought JNJ
Bill introduced
Lloyd Doggett bought JNJ
Jefferson Shreve bought JNJ
Josh Gottheimer sold JNJ
Read twice and referred to the Committee on Finance.
| Registrant | Client | Amount | Filed | Period | Issues |
|---|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $1288.0M | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $758.0M | Jul 21, 2025 | 2025Q2 | BUDCPTHCR |
Congress members who traded stocks in companies connected to lobbying on this bill, within 90 days of its introduction date.
| Member | Party | Ticker | Company | Trade | Date | Amount | Timing | Lobbying Client | Conflict |
|---|---|---|---|---|---|---|---|---|---|
| Lloyd Doggett | D | JNJ | JOHNSON & JOHNSON | Buy | Mar 4, 2025 | $1,001 - $15,000 | Same day | JOHNSON & JOHNSON SERVICES INC | 35% |
| Bruce Westerman | R |
61 trades by 13 members of Congress in companies connected to lobbying on S 832. The average conflict score is 32%.
CapitolExposed identifies the "bill-lobbying-trade pipeline" by: (1) finding lobbying filings (LD-2) that specifically mention this bill, (2) matching lobbying clients to publicly traded companies, and (3) finding stock trades by members of Congress in those companies within 90 days of the bill's introduction date. Trades made before the bill was introduced are highlighted in red, as they may indicate advance knowledge. This analysis surfaces correlations worthy of scrutiny; it does not prove wrongdoing.
Lobbying filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Lobbying filed by PFIZER INC.
Lobbying filed by NOVARTIS
Lobbying filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Lobbying filed by AARP
| AARP | AARP | $512.0M | Jul 21, 2025 | 2025Q2 | MMMHCRPHA |
| PFIZER INC. | PFIZER INC. | $424.0M | Apr 21, 2025 | 2025Q1 | BUDHCRMMM |
| NOVARTIS | NOVARTIS | $416.8M | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $411.3M | Apr 21, 2025 | 2025Q1 | MMMHCRPHA |
| PFIZER INC. | PFIZER INC. | $349.0M | Jul 21, 2025 | 2025Q2 | BUDHCRMMM |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $342.9M | Jul 21, 2025 | 2025Q2 | MMMHCRPHA |
| JOHNSON & JOHNSON SERVICES, INC. | JOHNSON & JOHNSON SERVICES INC | $334.0M | Apr 21, 2025 | 2025Q1 | PHASCITAX |
| BAYER CORPORATION (CONSOLIDATED REPORT) | BAYER CORPORATION (CONSOLIDATED REPORT) | $295.0M | Apr 21, 2025 | 2025Q1 | AGRMMMTAR |
| SANOFI US SERVICES INC. | SANOFI US SERVICES INC | $254.0M | Apr 21, 2025 | 2025Q1 | MANHCRMMM |
| BAYER CORPORATION (CONSOLIDATED REPORT) | BAYER CORPORATION (CONSOLIDATED REPORT) | $252.0M | Jul 21, 2025 | 2025Q2 | CPTHCRMMM |
| TAKEDA PHARMACEUTICALS AMERICA, INC. | TAKEDA PHARMACEUTICALS AMERICA INC | $152.0M | Jul 21, 2025 | 2025Q2 | BUDMMMHCR |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $151.0M | Jul 21, 2025 | 2025Q2 | BUDCPTHCR |
| BIOGEN | BIOGEN | $138.0M | Jul 20, 2025 | 2025Q2 | HCRMMMPHA |
| BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | BOEHRINGER INGELHEIM USA CORPORATION | $124.0M | Apr 21, 2025 | 2025Q1 | HCRMMMANI |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | OTSUKA AMERICA PHARMACEUTICAL, INC. | $118.0M | Apr 17, 2025 | 2025Q1 | HCRBUDTAX |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | OTSUKA AMERICA PHARMACEUTICAL, INC. | $116.0M | Jul 18, 2025 | 2025Q2 | TAXVETTAR |
| JOHNSON & JOHNSON SERVICES, INC. | JOHNSON & JOHNSON SERVICES INC | $103.0M | Jul 21, 2025 | 2025Q2 | HCRBUDCPT |
| BIOGEN | BIOGEN | $102.0M | Apr 21, 2025 | 2025Q1 | MMMPHAMAN |
| BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | BOEHRINGER INGELHEIM USA CORPORATION | $99.0M | Jul 21, 2025 | 2025Q2 | HCRMMMANI |
| EMD SERONO, INC. | EMD SERONO INC | $91.0M | Jul 21, 2025 | 2025Q2 | HCRMMMPHA |
| NEUROCRINE BIOSCIENCES, INC | NEUROCRINE BIOSCIENCES, INC | $91.0M | Apr 21, 2025 | 2025Q1 | MMMHCRBUD |
| EMD SERONO, INC. | EMD SERONO INC | $90.0M | Apr 21, 2025 | 2025Q1 | SCITRDHCR |
| NEUROCRINE BIOSCIENCES, INC | NEUROCRINE BIOSCIENCES, INC | $89.0M | Jul 21, 2025 | 2025Q2 | MMMHCRBUD |
| NOVARTIS | NOVARTIS | $88.0M | Jul 21, 2025 | 2025Q2 | BUDCPTHCR |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $80.0M | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| ACADIA PHARMACEUTICALS | ACADIA PHARMACEUTICALS | $50.0M | Jul 21, 2025 | 2025Q2 | TAXHCRMMM |
| TAKEDA PHARMACEUTICALS AMERICA, INC. | TAKEDA PHARMACEUTICALS AMERICA INC | $49.0M | Apr 22, 2025 | 2025Q1 | BUDTAXTRD |
| COVINGTON & BURLING LLP | PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | $42.0M | Apr 21, 2025 | 2025Q1 | CPTHCR |
| COVINGTON & BURLING LLP | PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | $22.0M | Jul 21, 2025 | 2025Q2 | CPTHCR |
| LUNDBECK LLC | LUNDBECK LLC | $17.0M | Jul 18, 2025 | 2025Q2 | HCRMMMTAX |
| HARMONY BIOSCIENCES | HARMONY BIOSCIENCES | $15.0M | Jul 21, 2025 | 2025Q2 | PHA |
| LUNDBECK LLC | LUNDBECK LLC | $14.0M | Apr 21, 2025 | 2025Q1 | HCRMMMTAX |
| PRIME THERAPEUTICS | PRIME THERAPEUTICS | $10.0M | Jul 16, 2025 | 2025Q2 | HCRMMMTRD |
| PUBLIC CITIZEN | PUBLIC CITIZEN | $9.9M | Jul 21, 2025 | 2025Q2 | BANBUDCIV |
| IONIS PHARMACEUTICALS, INC. | IONIS PHARMACEUTICALS, INC. | $9.0M | Jul 16, 2025 | 2025Q2 | HCRMMMTAX |
| PUBLIC CITIZEN | PUBLIC CITIZEN | $7.7M | Apr 9, 2025 | 2025Q1 | BANBUDCIV |
| DLA PIPER LLP (US) | BIOGEN, INC. | $6.0M | Jul 21, 2025 | 2025Q2 | PHACPTHCR |
| DLA PIPER LLP (US) | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $6.0M | Jul 21, 2025 | 2025Q2 | PHAHCRMMM |
| TODD STRATEGY GROUP | NOVARTIS, INC. | $6.0M | Jul 20, 2025 | 2025Q2 | MMMTARHCR |
| DLA PIPER LLP (US) | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $6.0M | Apr 21, 2025 | 2025Q1 | PHAHCRMMM |
| HEALTHCARE INSTITUTE OF NEW JERSEY | HEALTHCARE INSTITUTE OF NEW JERSEY | $5.3M | Apr 14, 2025 | 2025Q1 | HCR |
| HEALTHCARE INSTITUTE OF NEW JERSEY | HEALTHCARE INSTITUTE OF NEW JERSEY | $5.2M | Jul 7, 2025 | 2025Q2 | HCR |
| WILLIAMS AND JENSEN, PLLC | PHRMA | $5.0M | Jul 21, 2025 | 2025Q2 | HCRBUDDEF |
| CROSSROADS STRATEGIES, LLC | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $5.0M | Jul 19, 2025 | 2025Q2 | HCRMMMBUD |
| THE KPM GROUP DC LLC | SOLENO THERAPEUTICS, INC. | $5.0M | Jul 17, 2025 | 2025Q2 | HCR |
| HORIZON GOVERNMENT AFFAIRS | PHRMA | $5.0M | Jul 8, 2025 | 2025Q2 | HCR |
| WILLIAMS AND JENSEN, PLLC | PHRMA | $5.0M | Apr 21, 2025 | 2025Q1 | MMMHCRBUD |
| PERSONALIZED MEDICINE COALITION | PERSONALIZED MEDICINE COALITION | $4.6M | Jul 21, 2025 | 2025Q2 | HCRBUD |
| DLA PIPER LLP (US) | NOVARTIS | $4.0M | Jul 18, 2025 | 2025Q2 | PHAMEDCPT |
| DESIMONE CONSULTING, LLC | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | $3.0M | Jul 16, 2025 | 2025Q2 | PHA |
| LMH STRATEGIC SOLUTIONS | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $3.0M | Jul 15, 2025 | 2025Q2 | MMMPHA |
| DESIMONE CONSULTING, LLC | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | $3.0M | Apr 18, 2025 | 2025Q1 | PHA |
| ELITE STRATEGIC SERVICES | CONSERVATIVES FOR PROPERTY RIGHTS | $2.5M | Apr 7, 2025 | 2025Q1 | CPTHCRLBR |
| FAMILIES USA FOUNDATION, INC. | FAMILIES USA FOUNDATION INC | $1.8M | Jul 17, 2025 | 2025Q2 | HCRMMMPHA |
| ELITE STRATEGIC SERVICES | CONSERVATIVES FOR PROPERTY RIGHTS | $1.5M | Jul 1, 2025 | 2025Q2 | CPTHCRLBR |
| HARNED STRATEGIES LLC | JOB CREATORS NETWORK | $750K | Jul 21, 2025 | 2025Q2 | UNMBUDEDU |
| HARNED STRATEGIES LLC | JOB CREATORS NETWORK | $750K | Apr 20, 2025 | 2025Q1 | BUDEDUHCR |
| PFIZER INC |
| Buy |
| Mar 3, 2025 |
| $1,001 - $15,000 |
| 1d before |
| PFIZER INC. |
| 37% |
| Bruce Westerman | R | JNJ | JOHNSON & JOHNSON | Buy | Mar 3, 2025 | $1,001 - $15,000 | 1d before | JOHNSON & JOHNSON SERVICES INC | 37% |
| Jefferson Shreve | R | JNJ | JOHNSON & JOHNSON | Buy | Mar 5, 2025 | $15,001 - $50,000 | 1d after | JOHNSON & JOHNSON SERVICES INC | 36% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Sell | Mar 7, 2025 | $1,001 - $15,000 | 3d after | JOHNSON & JOHNSON SERVICES INC | 31% |
| Carol D. Miller | R | PFE | PFIZER INC | Sell | Mar 10, 2025 | $1,001 - $15,000 | 6d after | PFIZER INC. | 38% |
| Gilbert Ray Cisneros, Jr. | D | PFE | PFIZER INC | Buy | Feb 26, 2025 | $1,001 - $15,000 | 6d before | PFIZER INC. | 36% |
| Carol D. Miller | R | PFE | PFIZER INC | Sell | Mar 10, 2025 | $15,001 - $50,000 | 6d after | PFIZER INC. | 1% |
| Robert P. Bresnahan, Jr. | R | PFE | PFIZER INC | Buy | Feb 25, 2025 | $15,001 - $50,000 | 7d before | PFIZER INC. | 41% |
| Robert P. Bresnahan, Jr. | R | BIIB | BIOGEN INC. | Buy | Feb 25, 2025 | $1,001 - $15,000 | 7d before | BIOGEN | 37% |
| Jefferson Shreve | R | JNJ | JOHNSON & JOHNSON | Buy | Feb 24, 2025 | $15,001 - $50,000 | 8d before | JOHNSON & JOHNSON SERVICES INC | 36% |
| Jefferson Shreve | R | PFE | PFIZER INC | Buy | Feb 24, 2025 | $15,001 - $50,000 | 8d before | PFIZER INC. | 36% |
| Sheri Biggs | R | JNJ | JOHNSON & JOHNSON | Sell | Mar 19, 2025 | $15,001 - $50,000 | 15d after | JOHNSON & JOHNSON SERVICES INC | 18% |
| John Boozman | R | PFE | PFIZER INC | Sell | Feb 13, 2025 | $1,001 - $15,000 | 19d before | PFIZER INC. | 36% |
| John Boozman | R | PFE | PFIZER INC | Sell | Feb 13, 2025 | $1,001 - $15,000 | 19d before | PFIZER INC. | 36% |
| George Whitesides | D | JNJ | JOHNSON & JOHNSON | Sell | Mar 24, 2025 | $100,001 - $250,000 | 20d after | JOHNSON & JOHNSON SERVICES INC | 41% |
| George Whitesides | D | NVS | NOVARTIS AG | Sell | Mar 24, 2025 | $100,001 - $250,000 | 20d after | NOVARTIS | 41% |
| George Whitesides | D | NVS | NOVARTIS AG | Sell | Mar 24, 2025 | $100,001 - $250,000 | 20d after | NOVARTIS | 41% |
| Julie Johnson | D | PFE | PFIZER INC | Sell | Feb 12, 2025 | $1,001 - $15,000 | 20d before | PFIZER INC. | 36% |
| Gilbert Ray Cisneros, Jr. | D | JNJ | JOHNSON & JOHNSON | Buy | Mar 31, 2025 | $15,001 - $50,000 | 27d after | JOHNSON & JOHNSON SERVICES INC | 36% |
| Gilbert Ray Cisneros, Jr. | D | PFE | PFIZER INC | Sell | Mar 31, 2025 | $15,001 - $50,000 | 27d after | PFIZER INC. | 36% |
| Julie Johnson | D | JNJ | JOHNSON & JOHNSON | Sell | Apr 1, 2025 | $1,001 - $15,000 | 28d after | JOHNSON & JOHNSON SERVICES INC | 36% |
| Robert P. Bresnahan, Jr. | R | PFE | PFIZER INC | Sell | Apr 8, 2025 | $15,001 - $50,000 | 35d after | PFIZER INC. | 41% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 35d after | OTSUKA AMERICA PHARMACEUTICAL, INC. | 37% |
| Robert P. Bresnahan, Jr. | R | JNJ | JOHNSON & JOHNSON | Sell | Apr 8, 2025 | $1,001 - $15,000 | 35d after | JOHNSON & JOHNSON SERVICES INC | 37% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 35d after | JOB CREATORS NETWORK | 37% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 35d after | LUNDBECK LLC | 37% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 35d after | TAKEDA PHARMACEUTICALS AMERICA INC | 37% |
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 35d after | GSK (FKA GLAXOSMITHKLINE INC.) | 37% |
| Robert P. Bresnahan, Jr. | R | BIIB | BIOGEN INC. | Sell | Apr 8, 2025 | $1,001 - $15,000 | 35d after | BIOGEN | 37% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Sell | Apr 9, 2025 | $1,001 - $15,000 | 36d after | JOHNSON & JOHNSON SERVICES INC | 36% |
| Jefferson Shreve | R | PFE | PFIZER INC | Sell | Apr 11, 2025 | $15,001 - $50,000 | 38d after | PFIZER INC. | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 39d before | OTSUKA AMERICA PHARMACEUTICAL, INC. | 32% |
| Gilbert Ray Cisneros, Jr. | D | PFE | PFIZER INC | Sell | Jan 24, 2025 | $1,001 - $15,000 | 39d before | PFIZER INC. | 32% |
| Gilbert Ray Cisneros, Jr. | D | JNJ | JOHNSON & JOHNSON | Sell | Jan 24, 2025 | $1,001 - $15,000 | 39d before | JOHNSON & JOHNSON SERVICES INC | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 39d before | TAKEDA PHARMACEUTICALS AMERICA INC | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 39d before | GSK (FKA GLAXOSMITHKLINE INC.) | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 39d before | JOB CREATORS NETWORK | 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Jan 24, 2025 | $1,001 - $15,000 | 39d before | LUNDBECK LLC | 32% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Buy | Jan 24, 2025 | $1,001 - $15,000 | 39d before | JOHNSON & JOHNSON SERVICES INC | 31% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Buy | Jan 21, 2025 | $1,001 - $15,000 | 42d before | JOHNSON & JOHNSON SERVICES INC | 36% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Buy | Jan 16, 2025 | $1,001 - $15,000 | 47d before | JOHNSON & JOHNSON SERVICES INC | 36% |
| Julie Johnson | D | PFE | PFIZER INC | Sell | Jan 15, 2025 | $1,001 - $15,000 | 48d before | PFIZER INC. | 36% |
| Bruce Westerman | R | JNJ | JOHNSON & JOHNSON | Sell | Apr 21, 2025 | $1,001 - $15,000 | 48d after | JOHNSON & JOHNSON SERVICES INC | 14% |
| Bruce Westerman | R | PFE | PFIZER INC | Sell | Apr 21, 2025 | $1,001 - $15,000 | 48d after | PFIZER INC. | 14% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Apr 29, 2025 | $1,001 - $15,000 | 56d after | OTSUKA AMERICA PHARMACEUTICAL, INC. | 36% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Apr 29, 2025 | $1,001 - $15,000 | 56d after | GSK (FKA GLAXOSMITHKLINE INC.) | 36% |
| Gilbert Ray Cisneros, Jr. | D | JNJ | JOHNSON & JOHNSON | Sell | Apr 29, 2025 | $1,001 - $15,000 | 56d after | JOHNSON & JOHNSON SERVICES INC | 36% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Apr 29, 2025 | $1,001 - $15,000 | 56d after | TAKEDA PHARMACEUTICALS AMERICA INC | 36% |
| Gilbert Ray Cisneros, Jr. | D | PFE | PFIZER INC | Buy | Apr 29, 2025 | $1,001 - $15,000 | 56d after | PFIZER INC. | 36% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Apr 29, 2025 | $1,001 - $15,000 | 56d after | LUNDBECK LLC | 36% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Apr 29, 2025 | $1,001 - $15,000 | 56d after | JOB CREATORS NETWORK | 36% |
| Kevin Hern | R | JNJ | JOHNSON & JOHNSON | Sell | Dec 31, 2024 | $100,001 - $250,000 | 63d before | JOHNSON & JOHNSON SERVICES INC | 23% |
| Jefferson Shreve | R | JNJ | JOHNSON & JOHNSON | Sell | May 12, 2025 | $50,001 - $100,000 | 69d after | JOHNSON & JOHNSON SERVICES INC | 31% |
| Robert P. Bresnahan, Jr. | R | PFE | PFIZER INC | Buy | May 15, 2025 | $15,001 - $50,000 | 72d after | PFIZER INC. | 41% |
| Robert P. Bresnahan, Jr. | R | BIIB | BIOGEN INC. | Buy | May 15, 2025 | $1,001 - $15,000 | 72d after | BIOGEN | 37% |
| Josh Gottheimer | D | JNJ | JOHNSON & JOHNSON | Buy | Dec 12, 2024 | $1,001 - $15,000 | 82d before | JOHNSON & JOHNSON SERVICES INC | 1% |
| Lloyd Doggett | D | JNJ | JOHNSON & JOHNSON | Buy | Dec 10, 2024 | $1,001 - $15,000 | 84d before | JOHNSON & JOHNSON SERVICES INC | 0% |
| Gilbert Ray Cisneros, Jr. | D | PFE | PFIZER INC | Buy | May 30, 2025 | $1,001 - $15,000 | 87d after | PFIZER INC. | 21% |
| Gilbert Ray Cisneros, Jr. | D | JNJ | JOHNSON & JOHNSON | Buy | May 30, 2025 | $15,001 - $50,000 | 87d after | JOHNSON & JOHNSON SERVICES INC | 20% |
| Virginia Foxx | R | JNJ | JOHNSON & JOHNSON | Buy | Dec 6, 2024 | $1,001 - $15,000 | 88d before | JOHNSON & JOHNSON SERVICES INC | 3% |